Neuroprotective effects of ATPase inhibitory factor 1 preventing mitochondrial dysfunction in Parkinson's disease
Open Access
- 9 March 2022
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-10
Abstract
Mitochondrial dysfunction is a key element in the progression of Parkinson’s disease (PD). The inefficient operation of the electron transport chain (ETC) impairs energy production and enhances the generation of oxidative stress contributing to the loss of dopaminergic cells in the brain. ATPase inhibitory factor 1 (IF1) is a regulator of mitochondrial energy metabolism. IF1 binds directly to the F1Fo ATP synthase and prevents ATP wasting during compromised energy metabolism. In this study, we found treatment with IF1 protects mitochondria against PD-like insult in vitro. SH-SY5Y cells treated with IF1 were resistant to loss of ATP and mitochondrial inner membrane potential during challenge with rotenone, an inhibitor of complex I in the ETC. We further demonstrated that treatment with IF1 reversed rotenone-induced superoxide production in mitochondria and peroxide accumulation in whole cells. Ultimately, IF1 decreased protein levels of pro-apoptotic Bax, cleaved caspase-3, and cleaved PARP, rescuing SH-SY5Y cells from rotenone-mediated apoptotic death. Administration of IF1 significantly improved the results of pole and hanging tests performed by PD mice expressing human α-synuclein. This indicates that IF1 mitigates PD-associated motor deficit. Together, these findings suggest that IF1 exhibits a neuroprotective effect preventing mitochondrial dysfunction in PD pathology.Keywords
Funding Information
- National Research Foundation of Korea (2019R1A2C1004575, NRF-2019R1F1A1063744)
This publication has 54 references indexed in Scilit:
- IF1 limits the apoptotic-signalling cascade by preventing mitochondrial remodellingCell Death & Differentiation, 2013
- JNK3-Mediated Apoptotic Cell Death in Primary Dopaminergic Neurons2011
- Behavioral phenotyping of mouse models of Parkinson's diseaseBehavioural Brain Research, 2010
- Mitochondrial dysfunction in Parkinson's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- IF1: setting the pace of the F1Fo-ATP synthaseTrends in Biochemical Sciences, 2009
- Differential effects of mitochondrial Complex I inhibitors on production of reactive oxygen speciesBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2009
- The emerging role of autophagy in Parkinson's diseaseMolecular Brain, 2009
- Regulation of Mitochondrial Structure and Function by the F1Fo-ATPase Inhibitor Protein, IF1Cell Metabolism, 2008
- Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype α-synucleinNeuroscience, 2006
- GAMMA‐carboxyglutamate excretion and calcinosis in juvenile dermatomyositisArthritis & Rheumatism, 1982